Li Chai

This paper describes a method to recover and biobank CD34+ hematopoietic stem cells from clinical apheresis waste for hemoglobinopathy research, showing comparable yields and viability to peripheral blood samples.

This paper uses AI to identify and validate non-coding regulatory variants affecting RHD expression, showing strong agreement between predictions and experimental results.

This paper discovers and characterizes SH6, a small molecule degrader of ZBTB7A that increases fetal hemoglobin expression in erythroid cells and shows therapeutic potential for β-hemoglobinopathies.

This study identifies BM adipocyte-derived Resistin, regulated by RXR signaling, as critical for HSC self-renewal and hematopoietic regeneration after myeloablation.

This study identifies a new IMiD-independent drug targeting SALL4's ZFC4 domain, leading to significant tumor growth inhibition in vivo.

The paper identifies a compound that degrades both SALL4 isoforms, overcoming IMiD limitations in liver cancer treatment.

The paper identifies LEVER RNA as a regulator of ε-globin expression by inhibiting PRC2-mediated H3K27 methylation and disrupting promoter-LCR interactions.

CRISPR-DiR induces locus-specific demethylation and chromatin remodeling to reactivate the p16 gene.

This study shows that SALL4 can be induced in cancer cells to make them dependent on it, enabling targeted therapy with drugs like DAC and ENT.

The paper identifies the DNA binding domain and sequence of SALL4, discovers its target genes in liver cancer cells, and reveals its mechanism of gene regulation.